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Abstract: After failure of first-line chemotherapy for advanced
non-small cell lung cancer, many patients remain candidates to
receive further antitumor treatment. To guide clinical management
of these patients and to suggest priorities for clinical research, an
International Panel of Experts met in Naples (Italy) in April 2007.
Results and evidence-based conclusions are presented in this article.
Single-agent chemotherapy with docetaxel or pemetrexed is the
recommended option for unselected patients with performance sta-
tus 0 to 2 who are candidates for second-line chemotherapy for
advanced non-small cell lung cancer. Docetaxel has demonstrated
superiority compared with best supportive care. Pemetrexed has
been shown to be noninferior to docetaxel, with a more favorable
toxicity profile. Erlotinib is effective in pretreated patients, and can
be given second-line in patients not suitable or intolerant to chemo-
therapy, and in all patients as third-line treatment after failure of
second-line chemotherapy. Gefitinib failed to show superiority to
placebo as second- or third-line treatment, but it has been shown to
be noninferior to docetaxel. In selected patients such as lifetime
nonsmokers or those of East-Asian ethnicity, erlotinib, or gefitinib
(where licensed) may be considered as second-line treatment even if
they are fit for chemotherapy. Best supportive care in addition to
active treatment remains important for all patients, but may be the
exclusive option for patients unsuitable for more aggressive therapy.
Further research is mandatory, to find better treatments, and to
identify clinical and molecular predictive markers of efficacy, both
for chemotherapy and for novel biologic agents.
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Cisplatin-based chemotherapy is considered standard ofcare worldwide for patients with advanced non-small cell
lung cancer (NSCLC).1 Approximately one-third of patients
obtain an objective response with first-line chemotherapy,
and another 20 to 30% achieve temporary disease stabiliza-
tion. Unfortunately, all patients ultimately suffer progression.
At the time of disease progression, many patients still have a
good performance status (PS) and can be considered for
further active treatment. Until 2000, there was no evidence
supporting the efficacy of second-line treatment, although
chemotherapy was often offered to patients in good clinical
condition, based on the results of phase II trials of several
new drugs showing modest activity in pretreated NSCLC.2,3
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Oncology (ASCO) stated that “there is no current evidence
that either confirms or refutes that second-line chemotherapy
improves survival in patients with advanced NSCLC.”4 In
recent years, the efficacy of several drugs in the second-line
setting has been demonstrated in phase III trials, and second-
line treatment can now be considered a standard of care.5,6
Two chemotherapeutic agents, docetaxel and pemetrexed,
and the biologic drug erlotinib are currently approved for
clinical use in this setting.
METHODS
Search Strategy and Selection Criteria
With the aims of reviewing the available evidence,
obtaining a consensus on second-line treatment of advanced
NSCLC in clinical practice, and suggesting the priorities for
clinical research in this field, an International Panel of Ex-
perts Meeting and Conference took place in Naples, Italy, in
April 2007. The oncologists who formed the scientific panel
of the meeting were selected by the two chairmen (C.G. and
F.D.M.). Principal investigators of all the relevant published
trials and other opinion leaders in the field were invited. The
Meeting was supported by Roche. The sponsor was not in-
volved in panel discussion, nor in the preparation of manuscript.
Published data for this review were identified by a
PUBMED search, performed by each of the panellists on the
topic assigned. Only articles published in English were con-
sidered. Important references from relevant articles were also
included. Abstracts presented at the ASCO meetings and at
the International Association for Study of Lung Cancer,
European Society of Medical Oncology, and European Cancer
Conference meetings between 1997 and 2006 were searched.
For manuscript preparation, abstracts presented at the 2007
ASCO meeting, International Association for Study of Lung
Cancer meeting, and European Cancer Conference meeting
were also searched.
RESULTS AND RECOMMENDATIONS
Second-Line Therapy: Prognosis and Aims
of Treatment
Patients who experience disease progression during or
after first-line treatment for advanced NSCLC have a limited life
expectancy. Quality of life is often compromised by disease-
related symptoms, by residual toxicity of previous chemother-
apy, and by comorbid diseases. The aims of second-line treat-
ment should be palliation of symptoms, benefit in quality of life,
and prolongation of survival. The benefits of treatment should
outweigh toxicity and inconvenience to the patient. Neverthe-
less, the impact of treatment on the natural history of the disease
is modest. As shown in a recent review of 19 phase III trials,7 in
the second-line or later setting, the median objective response
rate was 6.8%, and median overall survival was 6.6 months.
Life expectancy of these patients is largely dependent
on their clinical condition at the start of second-line treat-
ment. Patients with PS 2, who are considered fit for further
treatment may have a relative benefit from treatment similar
to patients with better PS. Nevertheless, the absolute benefit
is small, with most studies reporting a median survival of 3 to
4 months. Overall survival of patients in an individual patient
data meta-analysis of phase III randomized trials comparing
weekly with every 3 weeks docetaxel8 was 32.7 weeks in
patients with PS 0, 29 weeks in patients with PS 1 and 14
weeks in patients with PS 2.
In a series of patients enrolled in a randomized trial of
second-line chemotherapy, other variables including gender,
stage, and best response to initial therapy as well as PS were
independently associated with survival.9 Median survival was
better in women, in patients with stage III compared with IV,
and in patients who had responded to first-line treatment.
The length of time spent by patients receiving antitu-
mor treatment has been increasing recently, due to the avail-
ability of new drugs. Nevertheless, most patients with ad-
vanced NSCLC who receive second-line treatment are near
the end of life. In a retrospective review of patients treated for
advanced NSCLC in a community oncology setting, the mean
line of chemotherapy in patients who were receiving active
treatment at the time of death was second-line.10 Chemother-
apy was given within 1 month and 2 weeks of death to 43 and
20% of patients, respectively. This can be explained in part
by the increased demand for additional treatment by patients and
their relatives who are unable to accept the futility of further
therapy and the inevitability of death from progressive NSCLC.
It may also be due to physicians’ inability to correctly predict life
expectancy of these patients. This emphasizes the importance of
identifying predictive markers of response, survival benefit, and
toxicity in pretreated NSCLC patients.
Role of Single-Agent Chemotherapy
Docetaxel
Docetaxel, 75 mg/m2 every 3 weeks, was the first drug to
be approved for second-line treatment of advanced NSCLC,
based on the results of 2 phase III trials (Table 1).11,12
In the TAX317 study,11 docetaxel 100 mg/m2 every 3
weeks was compared with best supportive care. When interim
safety data monitoring identified a significantly higher toxic
death rate in the chemotherapy arm, the protocol was
amended and the dose was reduced to 75 mg/m2. Median
overall survival was significantly longer for patients in the
chemotherapy arm (7.0 versus 4.6 months). Interestingly, all
quality of life parameters favored docetaxel, although the
statistically significant results favoring docetaxel were more
evident with the higher dosage.13 Febrile neutropenia was the
most relevant toxicity reported with docetaxel, but was less
frequent with the lower dose.
In the TAX320 trial,12 patients were randomized to
receive docetaxel (100 or 75 mg/m2, every 3 weeks) or to a
control arm of vinorelbine or ifosfamide at the investigator’s
discretion. Although overall response rates were significantly
higher and time-to-progression was significantly longer in the
docetaxel arms, median overall survival was not significantly
different among the three groups. Nevertheless, 1-year sur-
vival was significantly greater with docetaxel 75 mg/m2 than
with the control treatment. Patients assigned to docetaxel had
more neutropenia and febrile neutropenia compared with the
control arm, but the lower dose of docetaxel generally was
well tolerated.
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Retrospective pharmacoeconomic studies have shown
that the cost of second-line docetaxel in NSCLC is in keeping
with the cost of second-line treatment in other tumors, and is
within an acceptable range for health care interventions.14,15
Weekly scheduling of docetaxel may reduce toxicity,
particularly neutropenia and febrile neutropenia, in pretreated
NSCLC patients16,17 without decreasing efficacy. Several
randomized trials have been conducted, comparing weekly
TABLE 1. Randomized Trials of Single Agent Chemotherapy in Second-Line Treatment of Advanced NSCLC
Study (First
Author, Year of
Publication)
Main Eligibility
Criteria Treatment Arm
Patients
(n)
Response
Rate (%)
Median
Progression-Free
Survival
(mo)
Median
Overall
Survival
(mo)
1-yr
Survival
(%)
Shepherd, 2000 11 One or more prior
platinum-based
chemotherapy, PS 0–2
Best supportive care 100 — 1.5 4.6 19
TXT 100 or 75 mg/m2 every 3 w 104 5.8 2.4 7.0 29
TXT 100 mg/m2 every 3 w 49 6.3 n.a. 5.9 19
TXT 75 mg/m2 every 3 w 55 5.5 n.a. 7.5 37
Fossella, 2000 12 One or more prior
platinum-based
chemotherapy, PS 0–2
Vinorelbine or ifosfamide 123 0.8 1.8 5.6 19
TXT 100 mg/m2 every 3 w 125 10.8 1.9 5.5 21
TXT 75 mg/m2 every 3 w 125 6.7 2.0 5.7 32
Hanna, 2004 24 One prior chemotherapy for
advanced disease, PS 0–2
TXT 75 mg/m2 every 3 w 288 8.8 2.9 7.9 29.7
Pemetrexed 500 mg/m2 every 3 w 283 9.1 2.9 8.3 29.7
Ramlau, 2006 26 One prior chemotherapy,
PS 0–2
TXT 75 mg/m2 every 3 w 415 5 3.0 7.1 28.7
Topotecan 2.3 mg/m2 orally day
1–5 every 3 w
414 5 2.6 6.4 25.1
Bonomi, 2005 27 One prior chemotherapy,
PS 0–2
TXT 75 mg/m2 every 3 w 422 n.a. n.a. 6.9 29
Paclitaxel poliglumex 210 mg/m2
(PS 0–1) 175 mg/m2 (PS 2)
every 3 w
427 n.a. n.a. 6.9 25
Krzakowski, 2007 29 One prior platinum-based
chemotherapy, PS 0–2
TXT 75 mg/m2 every 3 w 277 5.5 2.3 7.2 n.a.
Vinflunine 320 mg/m2 every 3 w 274 4.4 2.3 6.7 n.a.
TXT, docetaxel; w, weeks; PS, performance status; mo, months.
TABLE 2. Randomized Trials of Every 3 wk vs. Weekly Schedule of Docetaxel in Second-Line Treatment of Advanced NSCLC
Study (First
Author, Year of
Publication) Phase Main Eligibility Criteria Docetaxel Schedule
Patients
(n)
Response
Rate (%)
Median
Overall
Survival
(mo)
1-yr
Survival
(%)
Febrile
Neutropenia
(%)
Gridelli, 2004 18 III One prior chemotherapy,
PS 0–2
75 mg/m2 every 3 w 110 2.7 6.7 21 5
33.3 mg/m2 weekly for 6 w,
then 2 w of rest
110 5.5 5.8 31 0
Gervais, 2005 19 II One prior platinum-based
chemotherapy, PS 0–2
75 mg/m2 every 3 w 62 4.8 5.8 18 6.5
40 mg/m2 weekly for 6 w,
then 2 w of rest
63 3.2 5.5 6 0
Schuette, 2005 20 III One or more prior
chemotherapy, PS 0–2
75 mg/m2 every 3 w 103 12.6 6.3 27 2
35 mg/m2 weekly for 3 w,
then 1 w of rest
105 10.5 9.2 39 1
Lai, 2005 22 II One prior chemotherapy,
PS 0–2
66 mg/m2 every 3 w 25 12 7.8 36 4
33 mg/m2 weekly for 2 w,
then 1 w of rest
25 24 7.3 36 1
Camps, 2006 21 III One prior platinum-based
chemotherapy, PS 0–2
75 mg/m2 every 3 w 129 9.3 6.6 27 8
36 mg/m2 weekly for 6 w,
then 2 w of rest
125 4.8 5.4 22 1
Chen, 2006 23 II One or more prior
platinum-based
chemotherapy, PS 0–2
75 mg/m2 every 3 w 33 6.1 9.5 29 12
40 mg/m2 weekly for 2 w,
then 1 w of rest
64 10.9 7.2 32 5
35 mg/m2 weekly for 3 w,
then 1 w of rest
64 17.2 8.4 33 2
mo, months; w, weeks; PS, performance status.
Gridelli et al. Journal of Thoracic Oncology • Volume 3, Number 4, April 2008
Copyright © 2008 by the International Association for the Study of Lung Cancer432
with the standard schedule of docetaxel in the second-line
treatment of advanced NSCLC and are summarized in Table
2.18–23 No trial had sufficient power to detect small, but
potentially relevant differences in overall survival. An indi-
vidual patient data meta-analysis, including five of these
randomized trials, has been published recently.8 Median
overall survival was similar, without significant heterogeneity
among the trials, and without relevant differential effect in
subgroup analyses. Significantly less severe neutropenia and
febrile neutropenia were confirmed with the weekly schedule
of docetaxel.
Pemetrexed
Pemetrexed is a multitargeted antifolate agent. Pem-
etrexed 500 mg/m2 was compared with docetaxel 75 mg/m2
in a phase III trial (Table 1).24 The study was originally
designed to test for superiority of pemetrexed, but in an
amendment to the protocol a noninferiority design was
adopted. Results were not sufficient to demonstrate the non-
inferiority of pemetrexed according to the fixed margin
method. Nevertheless, using the percent retention method,
results were adequate to define noninferiority. Patients re-
ceiving docetaxel experienced significantly higher rates of
severe neutropenia, febrile neutropenia, neutropenia with in-
fections and hospitalization due to neutropenic events. Al-
though neither superiority nor noninferiority for overall sur-
vival could be strictly demonstrated according to primary
efficacy analysis, comparable response rates and progression-
free survival times supported the conclusion that an effect of
pemetrexed on survival was reasonably likely. The trial
results led to drug approval.25
Other Cytotoxic Agents Tested in Phase III
Trials
Oral topotecan has been compared with standard do-
cetaxel in a phase III study that was designed to test the
noninferiority of oral topotecan (Table 1).26 One-year sur-
vival rates were 25.1% with topotecan and 28.7% with
docetaxel, and this difference met the predefined criteria for
noninferiority of topotecan. Nevertheless, median overall
survival was 27.9 weeks with topotecan and 30.7 weeks with
docetaxel and the higher survival rate with docetaxel was
maintained across the entire treatment period, although the
difference did not reach statistical significance. Grade 3/4
neutropenia occurred more frequently with docetaxel, while
grade 3/4 anemia and thrombocytopenia occurred more fre-
quently with topotecan. Patients receiving docetaxel had
significant advantages in quality of life compared with patients
receiving oral topotecan. At the moment, topotecan is not ap-
proved for the second-line treatment of advanced NSCLC.
Paclitaxel poliglumex (PP) is a macromolecular drug
conjugate that links paclitaxel with a biodegradable polymer
(poly-L-glutamic acid). The STELLAR II trial compared PP
with docetaxel as second-line therapy in patients with ad-
vanced NSCLC (Table 1).27 Patients assigned to PP experi-
enced significantly less hematological toxicity and less febrile
neutropenia. As for nonhematological toxicity, PP was asso-
ciated with a lower incidence of diarrhea, stomatitis, respira-
tory symptoms, and fatigue, but worse neuropathy. The trial
did not demonstrate any survival benefit for PP therapy when
compared with docetaxel. Although PP showed comparable
efficacy to standard docetaxel, with a favorable tolerability
profile, the study was not designed as a noninferiority trial,
and these results cannot be considered sufficient to recom-
mend PP as a standard approach. PP is not approved for
clinical use in the second-line treatment of advanced NSCLC.
Vinflunine is a new microtubule inhibitor of the vinca
alkaloid class with clinical activity in NSCLC.28 Vinflunine
was compared with docetaxel in a phase III trial in pretreated
NSCLC patients (Table 1).29 The primary end-point was
progression free survival, with a noninferiority analysis. All
efficacy endpoints including median progression free sur-
vival, response rate, and median overall survival were simi-
lar. Although the toxicity profile of the experimental arm was
judged manageable, vinflunine was characterized by higher
incidence of grade 3/4 anemia, abdominal pain, constipation,
and fatigue. Vinflunine is not yet approved by the Food and
Drug Administration (FDA, United States of America) or by
the European Medicines Agency (European Union) and its
use remains experimental.
Role of Combination Chemotherapy
In first-line treatment of good PS patients, doublet
chemotherapy has been shown to be more effective than
single-agent, both in terms of response and survival.30 In the
second-line setting, the clinical trials showing efficacy of
chemotherapy all tested single-agent treatment. With the aim
of obtaining better results, several trials compared a doublet
with single agent chemotherapy. Docetaxel was used in the
control arms in three of the trials31–33 whereas other single
agents were used in two studies enrolling patients who had
already received docetaxel as first-line treatment.34,35 These
trials are summarized in Table 3. Only one Japanese trial that
compared single-agent docetaxel with the combination of
docetaxel and gemcitabine had a phase III design.31 It was
terminated early after the report of an unexpectedly high
incidence of interstitial lung disease and three treatment-
related deaths (5%) due to interstitial lung disease, seen only
in combination arm. Considering all the trials, combination
chemotherapy is characterized by higher toxicity, with some
advantage in terms of objective response and progression-free
survival, but without a significant difference in overall sur-
vival. Nevertheless, with one exception,31 the trials were not
designed as comparative phase III trials, but were randomized
phase II trials, with a small sample size and inadequate
statistical power to exclude potentially relevant differences.
Role of Epidermal Growth Factor Receptor
Inhibitors
Epidermal Growth Factor receptor (EGFR) expression
is common in NSCLC, and the EGFR pathway has been the
target of development of new drugs against this disease.36
Erlotinib and gefitinib are small molecules that inhibit the
tyrosine kinase activity of EGFR and have been studied
extensively in advanced NSCLC.
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Erlotinib
Erlotinib was compared with placebo in the BR.21
phase III study (Table 4).37 Patients were eligible if they had
received one or two regimens of chemotherapy. Accrual
started in 2001, after the demonstration of the efficacy of
docetaxel in the second-line setting, but the placebo control
arm was considered ethical by the investigators, because
second-line patients were only included if they were not
eligible for further chemotherapy. In other words, these
patients are not comparable to the patients enrolled in the
clinical trials evaluating the efficacy of docetaxel and pem-
etrexed. Patients were randomized in a 2:1 ratio to receive
either erlotinib 150 mg orally daily or placebo. Statistically
significant and clinically relevant differences were observed
for progression-free survival and overall survival. This was
the first randomized trial to demonstrate that an EGFR ty-
rosine kinase inhibitor is able to prolong survival after che-
motherapy for advanced NSCLC. Treatment with erlotinib
also showed significant benefits in quality of life and lung
cancer-related symptoms of cough, dyspnea, and pain.38
Based on the results of the BR.21 study, erlotinib was
approved by the FDA in 2004 and is now approved world-
wide for the treatment of advanced NSCLC patients failing
after previous chemotherapy.39
TABLE 3. Randomized Trials of Combination vs. Single-Agent Chemotherapy in Second-Line Treatment of Advanced NSCLC
Study (First
Author, Year of
Publication) Phase Main Eligibility Criteria Treatment Arm
Patients
(n)
Response
Rate (%)
Median
Progression-Free
Survival
(mo)
Median
Overall
Survival
(mo)
1-yr
Survival
(%)
Takeda, 2004 31 III One prior platinum-based
chemotherapy, PS 0–1
Docetaxel 60 mg/m2 day 1 q3w 65 6.7 2.2 10.1 42
Docetaxel 60 mg/m2 day 8 65 7 3.0 10.2 46
Gemcitabine 800 mg/m2 day 1,
8 q3w
Wachters, 2005 32 II One prior chemotherapy Docetaxel 75 mg/m2 day 1 q3w 56 16 4.2 7.4 n.a.
Docetaxel 60 mg/m2 day 1 52 10 3.5 6.3 n.a.
Irinotecan 200 mg/m2 day 1 q3w
Pectasides, 2005 33 II Platinum refractory, Docetaxel 75 mg/m2 day 1 q3w 65 14 4.8 6.4 34
PS 0–2 Docetaxel 30 mg/m2 day 1, 8 65 20 5.6 6.5 37
Irinotecan 60 mg/m2 day 1, 8
q3w
Georgoulias, 2004 34 II Patients progressing after
cisplatin-docetaxel,
PS 0–2
Irinotecan 300 mg/m2 day 1 q3w 71 4 5.0 7 29
Gemcitabine 1000 mg/m2 day
1, 8
76 18 7.5 9 25
Irinotecan 300 mg/m2 day 8 q3w
Georgoulias, 2005 35 II Patients pretreated with
taxane  gemcitabine,
PS 0–2
Cisplatin 80 mg/m2 day 1 q3w 73 7 2.1 8.8 32
Cisplatin 80 mg/m2 day 8 74 22 2.6 7.8 34
Irinotecan 110 mg/m2 day 1,
100 mg/m2 day 8, q3w
w, weeks; mo, months; PS, performance status.
TABLE 4. Randomized Phase III Trials With EGFR Tyrosine Kinase Inhibitors in Second-Line Treatment of Advanced NSCLC
Study (First
Author, Year of
Publication) Main Eligibility Criteria Treatment Arm
Patients
(n)
Response
Rate (%)
Median
Progression-Free
Survival
(mo)
Median
Overall
Survival
(mo)
1-yr
Survival
(%)
Shepherd, 2005 37 One or 2 prior chemotherapy
regimens, unfit for further
chemotherapy, PS 0–3
Placebo 243 1 1.8 4.7 22
Erlotinib 150 mg daily 488 8.9 2.2 6.7 31
Thatcher, 2005 41 One or 2 prior chemotherapy
regimens, PS 0–3
Placebo 563 1 2.6a 5.1 21
Gefitinib, 250 mg daily 1129 8 3.0a 5.6 27
Niho, 2007 43 One or 2 chemotherapy
regimens, at least one
containing platinum, PS 0–2
Docetaxel 60 mg/m2 every
3 w
244 12.8 2.0 14.0 54
Gefitinib, 250 mg daily 245 22.5 2.0 11.5 48
Douillard, 2007 44 One or 2 chemotherapy
regimens, at least one
containing platinum, PS 0–2
Docetaxel 75 mg/m2 every
3 w
733 7.6 2.7 8.0 34
Gefitinib, 250 mg daily 733 9.1 2.2 7.6 32
a Time to treatment failure.
mo, months; w, weeks; PS, performance status.
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Gefitinib
In 2003, on the basis of encouraging phase II data,
gefitinib received accelerated approval by the FDA for pa-
tients with locally advanced or metastatic NSCLC, after
failure of both platinum-based and docetaxel chemothera-
pies.40 Nevertheless, no controlled phase III trial had demon-
strated gefitinib efficacy, and accelerated approval regula-
tions required the sponsor to conduct additional studies to
confirm the activity and efficacy of gefitinib.
Subsequently, gefitinib was compared with placebo in the
ISEL phase III trial, for patients with advanced NSCLCwho had
received one or two regimens of chemotherapy and who were
refractory to (defined as recurrent or progressive disease within
90 days of the last chemotherapy dose) or intolerant of their
latest chemotherapy regimen (Table 4).41 In this study, 1692
patients were randomly assigned in a 2:1 ratio to receive either
gefitinib (orally, 250 mg daily) or placebo, plus best supportive
care. The primary end-point of the trial was survival in the
overall population and in the subgroup of patients with adeno-
carcinoma. Overall survival did not differ significantly between
the groups, neither in the overall population nor among the 812
patients with adenocarcinoma. Because of these negative results,
the conditions of gefitinib approval have been restricted, and the
drug was relabeled by the FDA for use in patients already
receiving it and obtaining a clinical benefit.42 Gefitinib is not
presently available in the United States, Canada, or most Euro-
pean countries, but it remains approved in Asian countries
including India, Japan, and China.
Results of two phase III trials comparing gefitinib to
docetaxel in patients with NSCLC after one or two chemo-
therapy regimens have been presented recently (Table 4).43,44
These studies have not yet been published in a peer-reviewed
journal, but their results have been considered for this review,
because they add important evidence to the topic of choice
between chemotherapy and EGFR inhibitors. Both trials were
designed as noninferiority trials, with overall survival as the
primary end-point. In the smaller study, conducted in Japa-
nese patients by Niho et al.,43 according to predefined criteria,
noninferiority for gefitinib was not proven. Nevertheless, the
study design allowed cross-over, and the impact of postpro-
gression treatment on overall survival is difficult to assess.
Secondary end-points, such as objective response and pro-
gression-free survival, largely unaffected by subsequent ther-
apy, showed similar or superior efficacy for gefitinib. In the
INTEREST trial, 1466 patients in progression after one or
two chemotherapy regimens were randomized to docetaxel or
gefitinib.44 Results of the trial are summarized in Table 4. The
study met the primary end point of demonstrating noninferi-
ority of gefitinib related to docetaxel in terms of overall
survival, in a population of patients not selected for molecular
characteristics.
Predictive Factors of Benefit from Erlotinib
or Gefitinib
Clinical benefit from the administration of erlotinib and
gefitinib appears greater in certain subgroups of patients, but
currently it is not possible to identify patients who will not
derive benefit from treatment. Efforts have been made to
identify predictive factors of the activity and efficacy of
treatment with erlotinib and gefitinib. Potential predictive
factors for antitumor efficacy of EGFR inhibitors in patients
with advanced NSCLC can be divided into several categories:
clinical characteristics, pathologic characteristics, and molec-
ular characteristics.
In BR.21, objective response to erlotinib was more
frequent in women, in patients with adenocarcinoma, in
patients with East-Asian ethnicity and in patients who had
never smoked.37 Nevertheless, the objective response rate
obtained with EGFR tyrosine-kinase inhibitors in unselected
patients is similar, if not higher, to the results obtained with
cytotoxic agents.11,12,24 Furthermore, relatively higher activ-
ity in selected subgroups of patients should not be interpreted
as a proof that the efficacy is limited to those patients. The
correlation between a surrogate end-point (objective re-
sponse) and overall survival in advanced NSCLC is even
debated for cytotoxic drugs.45 With targeted agents, the
concept that clinical benefit is limited to the occurrence of an
objective response is even weaker.46 Subgroup analyses of
the BR.21 trial show that erlotinib had a beneficial effect on
survival in almost all subgroups tested.37 A significant inter-
action was only found between smoking history and treat-
ment, with erlotinib showing superiority compared with pla-
cebo in never smokers, but not in smokers.37,47 These results
are similar to those obtained with gefitinib in the ISEL trial,41
where significant benefit was shown for gefitinib over pla-
cebo in never-smokers, but not in smokers. Preplanned sub-
group analyses showed significantly longer survival in gefitinib-
treated patients of East-Asian ethnicity and for never-smokers.
Nevertheless, these data should not be seen as a proof of the
absence of efficacy of EGFR inhibitors in smokers. In an
unplanned subset analysis of BR.21, despite a very low tumor
response rate, male ever-smokers with squamous cell NSCLC
derived a significant survival benefit from erlotinib.47
Analyses of the predictive role of molecular markers in
the BR.21 and ISEL trials48–50 are summarized in Table 5.
According to the results of molecular analyses, selection or
exclusion of patients for treatment with EGFR inhibitors
should not be based on EGFR protein expression, as deter-
mined by immunohistochemistry.51 In recent years, it has
been repeatedly shown that a substantial percentage of tumors
with objective response to gefitinib or erlotinib harbor so-
matic mutations in the EGFR gene.52–55 Nevertheless, at the
present, there are no definitive data to consider mutational
analysis necessary to identify patients for treatment with
EGFR inhibitors, since patients with wild-type EGFR clearly
derive considerable survival benefit from treatment. Simi-
larly, the analysis of KRAS mutational status has no estab-
lished role in the management of patients who are candidates
to receive erlotinib. Fluorescence in situ hybridization can
determine the number of gene copies of EGFR in tumor cell
DNA.49 Further prospective studies are needed before a
conclusion can be made about the role of EGFR gene ampli-
fication as a predictive test for efficacy of an EGFR inhibitor,
although at this time, it appears that this may be the most
sensitive test to predict for a differential survival benefit from
EGFR tyrosine kinase inhibitor therapy. In the INTEREST
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trial, there was no evidence that high EGFR gene copy
number, measured by fluorescence in situ hybridization, pre-
dicted superior survival for gefitinib over docetaxel.44 In the
subset of 174 patients with high EGFR copy number, median
overall survival was 7.5 months with docetaxel and 8.4
months with gefitinib, and this difference was not statistically
significant.
CONSENSUS FOR CLINICAL PRACTICE
Who should be Treated?
Only patients with clinical and/or radiologic evidence
of disease progression after or during first-line chemotherapy
should be considered for second-line treatment. In patients
achieving objective response or disease stabilization with
first-line therapy, maintenance treatment with the same or
different agents has not definitively been shown to improve
overall survival, and should not be considered a standard
approach.56–59 In a recent trial,59 307 stable and responding
patients were randomized to receive docetaxel either imme-
diately after first-line chemotherapy or on disease progres-
sion. Median overall survival showed a trend favoring imme-
diate treatment, but the difference did not reach statistical
significance.
Clinical trials showing efficacy of second-line chemo-
therapy were limited to patients with good or intermediate PS
(ECOG 0–2).8,11,12,24 There is no evidence supporting the
effectiveness of second-line chemotherapy in patients with
worse PS. In BR.21, patients with PS 2–3 were eligible, and
according to subgroup analysis, erlotinib was beneficial in
these patients.37 Nevertheless, the decision to treat a patient
in poor clinical condition should be based on careful evalu-
ation of the expected toxicity profile and of the potential
benefit in terms of survival and of symptom control.
To date, there are no clinical trials of second-line
therapy dedicated to elderly patients. The only evidence of
efficacy of second-line treatment in the elderly patients comes
from retrospective subgroup analyses.60 Particular caution
should be used when treating elderly patients, considering the
palliative aim of second-line treatment and the higher risk of
toxicity in these patients.
Which Treatment?
To date, the study conducted in Japanese patients and
the INTEREST trial, comparing gefitinib to docetaxel, are the
only available comparison between chemotherapy and an
EGFR inhibitor in patients who are candidates for second-line
treatment.43,44 These trials have not yet been published in a
peer-reviewed journal. In the Japanese trial, noninferiority of
gefitinib was not proven, but the study has several limitations,
because the primary end-point could have been affected by
cross-over. In the INTEREST trial, characterized by a larger
sample size, primary end point of noninferiority of gefitinib
was met. According to this study, gefitinib represents a
reasonable option for second-line treatment of patients with
advanced NSCLC. Nevertheless, definitive publication of
these results, and results from other trials currently ongoing
should be awaited.
Which Chemotherapy?
According to the results of phase III trials, chemo-
therapy with one approved drug (docetaxel or pemetrexed)
should be the first choice in patients with good PS, expe-
riencing disease progression during or after first-line treat-
ment. Although a retreatment strategy is sometimes considered
in patients with long progression-free intervals after first-line
treatment, there are no randomized data supporting this strat-
egy. With the evidence currently available, there is no estab-
lished role for other single agents, or for combination che-
motherapy. These and other undefined issues for the second-line
chemotherapy of advanced NSCLC in clinical practice are listed
in Table 6.
TABLE 5. Analysis of Molecular Predictive Factors in the BR.21 and ISEL Trials
BR.21 49,50 ISEL 48
Number of
Samples
HR For
Survival p
Test For
Interaction
Multivariate
Analysis
Number
of
Samples
HR For
Survival p
Test For
Interaction
Multivariate
Analysis
EGFR expression 325 Not significant
(0.25)
Not
significant
379 0.049 Not feasible
Negative 141 (43%) 0.68 (0.49–0.95) 0.02 115 (30%) 1.57 (0.86–2.87) 0.140
Positive 184 (57%) 0.93 (0.63–1.36) 0.70 264 (70%) 0.77 (0.56–1.08) 0.126
EGFR copy
number
159 Not significant
(0.12)
0.009 370 0.045 Not feasible
Low 98 (62%) 0.80 (0.49–1.29) 0.35 256 (69%) 1.16 (0.81–1.64) 0.417
High 61 (38%) 0.43 (0.23–0.78) 0.004 114 (31%) 0.61 (0.36–1.04) 0.067
EGFR mutational
status
204 Not significant
(0.47)
Not
significant
215 The limited amount of data prevents meaningful
evaluation of clinical outcomes in relation to
these mutationsWild-type 170 (83%) 0.74 (0.52–1.05) 0.09 189 (88%)
Mutated 34 (17%) 0.55 (0.25–1.19) 0.12 26 (12%)
KRAS mutational
status
206 Not significant
(0.09)
Not
significant
152 The limited amount of data prevents meaningful
evaluation of clinical outcomes in relation to
these mutationsWild-type 176 (85%) 0.69 (0.49–0.97) 0.03 140 (92%)
Mutated 30 (15%) 1.67 (0.62–4.50) 0.31 12 (8%)
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Standard docetaxel is administered 75 mg/m2 every 3
weeks.11,12 Weekly docetaxel produces significantly less he-
matological toxicity, with comparable efficacy, and may be
considered as an alternative.8 Nevertheless, some clinicians
feel that the inconvenience of the weekly schedule is not
justified, given the availability of other drugs administered in
more convenient schedules.61 The clinical trials comparing
weekly with every 3-week docetaxel used different doses and
schedules in the weekly arms, and there is no evidence of
superiority of one of these schedules.
EGFR Inhibitors
Based on the BR.21 trial,37 erlotinib should be admin-
istered as second-line treatment in patients considered unfit
for chemotherapy or as third-line treatment. The negative
results of the ISEL trial41 discouraged the use of gefitinib in
unselected patients, but the recently reported results of the
INTEREST trial, conducted in patients who were fit for
further chemotherapy after the failure of one or two previous
chemotherapy regimens,44 support the consideration of EGFR
inhibitors as a reasonable alternative to second-line chemo-
therapy.
At present, there is no evidence to recommend the
routine use of molecular marker analysis (EGFR expression,
EGFR gene mutations, KRAS or other gene mutations, EGFR
gene copy number) to select patients for treatment with
EGFR inhibitors.
Research Issues in Second-Line Treatment of
Advanced NSCLC
A number of questions concerning second-line treat-
ment of advanced NSCLC remain to be answered. Questions,
that in the opinion of the panellists should drive future
clinical research in this field, are reported in Table 7.
Chemotherapy seems to have reached a plateau in
efficacy, and it is unlikely that significant advances would
come from new chemotherapeutic agents. For this reason,
clinical research to answer remaining questions regarding
chemotherapy is of low priority. Of greater relevance are the
questions regarding biologic agents, and in particular EGFR
inhibitors. Comparison between standard chemotherapy and
an EGFR inhibitor in unselected patients, and in patients
positively or negatively selected for the presence of predic-
tive factors is a research issue of high priority. Results of
trials comparing gefitinib to docetaxel have recently given the
first important evidences regarding this issue.43,44 Further
phase III trials comparing an EGFR inhibitor with chemo-
therapy are currently ongoing; some of these studies are
conducted in unselected population, others in patients se-
lected according to the presence of molecular predictive
factors. Both types of trials will give important answers for
clinical practice. Another interesting issue is the optimal
sequence of chemotherapy and EGFR inhibitors. The
TORCH phase III trial, conducted in Italy and Canada, is
currently assessing in unselected patients whether an exper-
imental strategy including first-line erlotinib followed at pro-
gression by cisplatin-based chemotherapy is not inferior in
terms of survival to the standard treatment of first-line che-
motherapy, followed at progression by erlotinib.
Of course, of great importance is the conduct of clinical
trials testing the activity of other new drugs. The low objec-
tive response rate usually obtained in second-line treatment
can result in premature rejection of potentially useful drugs,
if end-points alternative to objective response are not prop-
erly identified and applied.62 Among drugs under clinical
development in second-line treatment of advanced NSCLC
are new molecules targeting the EGFR pathway63 and several
drugs targeting the vascular endothelial growth factor
(VEGF) pathway.64 In particular, there is strong biologic
rationale for therapeutic approaches targeting both path-
ways.65 Bevacizumab, a monoclonal antibody against VEGF,
has shown promising results in advanced, nonsquamous
NSCLC, in a randomized phase II trial, both in combination
with chemotherapy and in combination with erlotinib.66 In
particular, the bevacizumab plus erlotinib combination, tar-
geting both VEGF and EGFR pathways, may represent an
attractive alternative to chemotherapy in relapsed NSCLC, if
the results are confirmed in a fully powered phase III trial.
Vandetanib (ZD6474) is a multitarget tyrosine kinase inhib-
itor, inhibiting two key pathways in tumor growth. Vandet-
anib showed promising results in randomized phase II trials,
both as a single agent67 and in combination with chemother-
apy.68 Among EGFR inhibitors, a number of newer mole-
cules are currently in clinical development. These include
monoclonal antibodies, such as panitumumab and matu-
TABLE 6. Undefined Issues in the Administration of Second-Line Chemotherapy of Advanced NSCLC in Clinical Practice
Maintenance treatment after first-line Maintenance treatment after first-line vs. second-line treatment after progressive disease?
Currently, there is no definitive evidence from randomized trials pro or contra this strategy
Maintenance studies with erlotinib, gefitinib, gemcitabine, and pemetrexed are currently on-going
Optimal duration of treatment Limited number of cycles?
Continuing treatment until progressive disease or unacceptable toxicity?
Rechallenge with drugs used in first-line Re-induction with drugs obtaining objective response in first-line in patients with a long progression-free
interval?
Currently, there is no evidence from randomized clinical trials pro or contra this strategy
Role of other cytotoxic drugs as single-agent Other drugs besides those showing positive results (docetaxel, pemetrexed) or negative results (topotecan,
vinorelbine)?
Currently, there are no randomized phase III trials supporting a role of other single-agent chemotherapy
Costs What role should be given to pharmacoeconomic considerations in the choice of second-line treatment?
3rd line Is there a role for further administration of chemotherapy in patients failing second-line treatment?
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zumab; dual inhibitors of EGFR and VEGF receptor, such as
vandetanib and AEE788, inhibitors of multiple EGFR family
members, and irreversible inhibitors, such as canertinib and
HKI272.63 Preclinical studies suggest that some of these
agents may have activity in tumors refractory to erlotinib or
gefitinib. Further research is needed to elucidate the role of
these agents in patients with EGFR inhibitor-naive and EGFR
inhibitor-refractory disease, to define the molecular charac-
teristics that predict response, and to determine whether these
drugs should be used in combination with other targeted
agents or chemotherapy.
The discovery and validation of predictive markers of
the efficacy, both for chemotherapy and for new drugs using
biologic samples, is a research strategy of high priority. The
availability of clinical or molecular factors that are able to
predict sensitivity, resistance and even toxicity will be critical
for patient selection. There has been little progress in the use
of molecular testing to identify patients for standard chemo-
therapy. Nevertheless, this will likely not be the case for the
molecularly targeted agents, and recent studies also suggest
that it may be possible to predict benefit using molecular tests
for chemotherapy as well.
Available pharmacoeconomic studies on second-line
treatment are retrospective models, with important limita-
tions. Prospective pharmacoeconomic analysis of second-line
treatment, in the opinion of the panelists would be useful to
inform clinical practice in this setting.
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